MLchartDataset catalogue

anti-PVRIG monoclonal antibody NM1F

Term · Oncology and biomedicine · MLC-T-ONC-011067

A humanized immunoglobulin G1 (IgG1) monoclonal antibody against poliovirus receptor-related immunoglobulin (PVRIG; PVR related immunoglobulin domain containing protein; CD112R), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PVRIG monoclonal antibody NM1F targets and binds to PVRIG expressed on cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells within the tumor microenvironment (TME). This blocks the interaction of PVRIG with its ligand nectin cell adhesion molecule 2 (poliovirus receptor-related 2; PVRL2; CD112), which is overexpressed on a variety of tumor cell types. Inhibiting the activation of PVRIG abrogates the PVRIG-induced inhibition of T-lymphocyte and NK cell activation. This activates CTLs and NK cells, enhances anti-tumor responses and immune-mediated tumor cell killing, and inhibits tumor cell proliferation. PVRIG, a member of the B7/CD28 family and an immune checkpoint receptor that, upon activation, negatively regulates the activation of various immune cells. It plays a key role in immunosuppression.

Table 1. Record
IdentifierMLC-T-ONC-011067
FieldOncology and biomedicine
Synonymsanti-PVRIG monoclonal antibody TGI-2; anti-CD112R monoclonal antibody NM1F
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-011067",
  "term": "anti-PVRIG monoclonal antibody NM1F",
  "field": "Oncology and biomedicine",
  "definition": "A humanized immunoglobulin G1 (IgG1) monoclonal antibody against poliovirus receptor-related immunoglobulin (PVRIG; PVR related immunoglobulin domain containing protein; CD112R), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PVRIG monoclonal antibody NM1F targets and binds to PVRIG expressed on cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells within the tumor microenvironment (TME). This blocks the interaction of PVRIG with its ligand nectin cell adhesion molecule 2 (poliovirus receptor-related 2; PVRL2; CD112), which is overexpressed on a variety of tumor cell types. Inhibiting the activation of PVRIG abrogates the PVRIG-induced inhibition of T-lymphocyte and NK cell activation. This activates CTLs and NK cells, enhances anti-tumor responses and immune-mediated tumor cell killing, and inhibits tumor cell proliferation. PVRIG, a member of the B7/CD28 family and an immune checkpoint receptor that, upon activation, negatively regulates the activation of various immune cells. It plays a key role in immunosuppression.",
  "synonyms": [
    "anti-PVRIG monoclonal antibody TGI-2",
    "anti-CD112R monoclonal antibody NM1F"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-pvrig-monoclonal-antibody-nm1f/"
}

Record 2,200 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.